中南药学

参考文献

[1]中华医学会外科学分会.应激性粘膜病变预防与治疗--中国普外科专家共识(2015)[J].中国实用外科杂志,2015,35(7):728-730.

[2]应激性溃疡防治专家组.应激性溃疡防治专家建议(2015版)[J].中华医学杂志,2015,95(20):1555-1557.

[3]Cook DJ,Fuller HD,Guyatt GH,et al.Risk factors for gastrointestinal bleeding in critically ill patients.Canadian Critical Care Trials Group[J].N Engl J Med,1994,330(6):377-381.

[4]Herziq SJ,Roehberg MB,Feinbloom DB,et al.Risk factors for nosocomial gastrointestinal bleeding and use of acid-suppressive medication in non-critically ill patients[J].J Gen Intern Med,2013,28(5):683-690.

[5]Grube RR,May DB.Stress ulcer prophylaxis in hospitalized patients not in intensive care units[J].Am J Health Syst Pharm,2007,64(13):1396-1400.

[6]Spirt MJ,Stanley S.Update on stress ulcer prophylaxis in critically ill patients[J].Crit Care Nurse,2006,26(1):18-20,22-28.

[7]EAST practice management guidelines committee.Practice management guidelines for stress ulcer prophylaxis[EB/OL].www.east.org/Content/documents/practice management guidelines/stress-ulcer-prophylaxis.

[8]Messori A,Fadda V,Maratea D,et al.Intravenous proton pump inhibitors for stress ulcer prophylaxis in critically ill patients:determining statistical equivalence according to evidence-based methods[J].Int J Clin Pharmacol Ther,2014,52(10):825-829.

[1]抗血小板药物消化道损伤的预防和治疗中国专家共识(2012更新版)[J].中华内科杂志,2013,52(3):264-268.

[1]中华消化杂志编委会.消化性溃疡病诊断与治疗规范(2013年深圳)[J].中华消化杂志,2014,34(2):73-76.

[2]中国医院协会药事管理专业委员会.质子泵抑制剂临床应用的药学监护[M].北京:人民卫生出版社,2013.

[1]中国医药协会药事管理专业委员会.质子泵抑制剂临床应用的药学监护[M].1版.北京:人民卫生出版社,2013.

[1]廖家智.美国急性胰腺炎临床指南[J].中国消化内镜,2007,1(10):37-48.

[2]李鸿,羊伟峰.奥美拉唑治疗急性胰腺炎的疗效观察[J].海峡药学,2010,22(12):186-187.

[3]中华医学会消化病学会分会胰腺疾病学组.中国急性胰腺炎诊治指南(2013年,上海)[J].中华消化杂志,2013,33(4):217-222.

[4]中华医学会外科学分会胰腺外科学组.急性胰腺炎诊治指南(2014)[J].中国实用外科杂志,2015,35(1):4-7.

[5]中华医学会外科学分会胰腺外科学组.慢性胰腺炎诊治指南(2014)[J].指南与共识,2015,35(3):277-282.

[6]高申,邹多武.质子泵抑制剂临床应用的药学监护[M].北京:人民卫生出版社,2013:88-93.

[7]丁国平.大剂量奥美拉唑治疗20例重症胰腺炎的疗效观察[J].医学综述,2013,19(20):3826-3827.

[8]田笑笑,杜浩,白艳丽,等.埃索美拉唑联合早期肠内营养治疗重症急性胰腺炎的临床研究[J].实用医学杂志,2015,31(10):1695-1698.

[9]缪建国.两种质子泵抑制剂联合生长抑素治疗重症急性胰腺炎的临床比较[J].现代诊断与治疗,2014,15(25):3495-3496.

[10]Youssef SS,Iskandar SB,Scruggs J,et al.Acute pancreatitis associated with omeprazole[J].Int J Clin Pharmacol Ther,2005,43(12):558-561.

[11]Das,Ganguly,Ghosh,et al.Oral pantoprazole-induced acute pancreatitis in an 11-Year-Old Child[J].Ther Drug Monit,2012,34(3):242-244.

[12]Concept-S?MK AEY,Design-S?EA,Supervision-HSRA,et al.Lansoprazole-induced acute pancreatitis[J].Turk J Gastroenterol,2014,25(5):582-583.

[1]Hata M,Shiono M,Sekino H,et al.Prospective randomized trial for optimal prophylactic treatment of the upper gastrointestinal complications after open heart surgery[J].Circ J,2005,69(3):331-334.

[2]Fujita K,Hata M,Sezai A,et al.Is prophylactic intravenous administration of a proton pump inhibitor necessary for perioperative management of cardiac surgery?[J].Heart Surg Forum,2012,15(5):E277-279.

[3]Bateman BT,Bykov K,Choudhry NK,et al.Type of stress ulcer prophylaxis and risk of nosocomial pneumonia in cardiac surgical patients:cohort study[J].BMJ,2013,347:f5416.

[4]Fisher L,Fisher A,Pavli P,et al.Perioperative acute upper gastrointestinal haemorrhage in older patients with hip fracture:incidence,risk factors and prevention[J].Aliment Pharmacol Ther,2007,25(3):297-308.

[5]Lalmohamed A,Vestergaard P,Javaid MK,et al.Risk。,,,,、,of gastrointestinal bleeding in patients undergoing total hip or knee replacement compared with matched controls:a nationwide cohort study[J].Am J Gastroenterol,2013,108(8):1277-1285.

[6]Takeuchi T,Ota K,Harada S,et al.The postoperative bleeding rate and its risk factors in patients on antithrombotic therapy who undergo gastric endoscopic submucosal dissection[J].BMC Gastroenterol,2013,13:136.

[7]Chen C,Shi Y,Zhang XP,et al.Risk factors associated with stress ulcer bleeding in postoperative rectal cancer patients[J].Zhonghua Wei Chang Wai Ke Za Zhi,2012,15(12):1277-1281.

[8]Stephenson KA,Fagan JJ.Effect of perioperative proton pump inhibitors on the incidence of pharyngocutaneous fistula after total laryngectomy:a prospective randomized controlled trial[J].Head Neck,2015,37(2):255-259.

[9]Han JB,Keller EE,Grothe RM.Postoperative gastrointestinal bleeding in orthognathic surgery patients:its estimated prevalence and possible association to known risk factors[J].J Oral Maxillofac Surg,2014,72(10):2043-2051.

[10]Guillamondegui OD,Gunter OL,Bonaides JA,et al.Practice management guidelines for stress ulcer prophylaxis[J].Eastern Association for the surgery of Trauma,2008:1-24.

[11]Daley RJ,Rebuck JA,Welage LS,et al.Prevention of sress ulceration:current trends in critical care[J].Crit Care Med,2004,32(10):2008-2013.

[12]Hurt RT,Frazier TH,Mc Clave SA,et al.Stress prophylaxis in intensive care unit patients and the role of enteral nutrition[J].J Parenter Enteral Nutr,2012,36(6):721-731.

[13]Pisegna JR,Sostek MB,Monyak JT,et al.Intravenous esomeprazole 40 mg vs.intravenous lansoprazole 30 mg for controlling intragastric acidity in healthy adults[J].Aliment Pharmacol Ther,2008,27(6):483-490.

[14]Wilder-Smith C H,R?hss K,Bondarov P,et al.Esomeprazole 40 mg i.v.provides faster and more effective intragastric acid control than pantoprazole 40 mg i.v.:results of a randomized study[J].Aliment Pharmacol Ther,2004,20(10):1099-1104.